(Q35936734)

11 August 2017

title

Observational study of the effects of using montelukast vs fluticasone in patients matched at baseline (English)

1 reference

11 August 2017

5

Kevin B Weiss

1 reference

11 August 2017

4

Leona E Markson

1 reference

11 August 2017

Felicia C Allen-Ramey

series ordinal

1

object named as

Felicia C Allen-Ramey

1 reference

11 August 2017

Phong T Duong

2

1 reference

11 August 2017

Aylin A Riedel

series ordinal

3

1 reference

11 August 2017

publication date

1 October 2004

1 reference

Annals of Allergy, Asthma & Immunology

11 August 2017

published in

1 reference

11 August 2017

volume

93

1 reference

11 August 2017

issue

4

1 reference

11 August 2017

page(s)

373-380

1 reference

Impact of inhaled antiinflammatory therapy on hospitalization and emergency department visits for children with asthma

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

Inhaled steroids and the risk of hospitalization for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

Outpatient management practices associated with reduced risk of pediatric asthma hospitalization and emergency department visits

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

Decrease in hospitalization for treatment of childhood asthma with increased use of antiinflammatory treatment, despite an increase in prevalence of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

Fluticasone is associated with lower asthma-related costs than leukotriene modifiers in a real-world analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

"Real-world" effectiveness of daily controller medicine in children with mild persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

The risk of hospitalization in patients with asthma switched from an inhaled corticosteroid to a leukotriene receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

Invited commentary: propensity scores

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

Early statin initiation and outcomes in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

Approaching value in asthma management: the need to integrate clinical and economic research with the basic science

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

Estimating causal effects from large data sets using propensity scores

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

Adherence to oral montelukast and inhaled fluticasone in children with persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

Adherence to Prescribed Treatment for Asthma: Evidence from Pharmacy Benefits Data

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

Relationship of adherence to pediatric asthma morbidity among inner-city children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

Overcoming barriers to nonadherence in asthma treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

Physicians' characteristics influence patients' adherence to medical treatment: Results from the Medical Outcomes Study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

Treatment preferences of adolescent patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

Insight into patient dissatisfaction with asthma treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

Impact of respiratory symptoms on health-related quality of life and medical resource utilization of patients treated by allergy specialists and primary care providers

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961397-X

7 January 2021

10.1016/S1081-1206(10)61397-X

Identifiers

DOI

1 reference

11 August 2017

1 reference